Last reviewed · How we verify
Combination Cinacalcet with Vitamin D analogue
The combination of Cinacalcet with a Vitamin D analogue, marketed by Penang Hospital, Malaysia, holds a niche position in the treatment landscape. The key composition patent expiring in 2028 provides a period of exclusivity, which is a significant competitive advantage. However, the lack of detailed revenue data and key trial results poses a primary risk, as it limits the ability to assess market performance and clinical efficacy compared to competitors.
At a glance
| Generic name | Combination Cinacalcet with Vitamin D analogue |
|---|---|
| Sponsor | Penang Hospital, Malaysia |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: